Sunstone (Tangshan) Pharmaceuticals, the Chinese
subsidiary of US speciality pharma concern BMP Sunstone, is acquiring a
75% holding in Zhangjiakou Shengda Pharmaceutical, a Chinese
manufacturer of paediatric pharmaceuticals and specialising in
antibiotic R&D, for around $4.4m.
by Eisberg, Neil
Sunstone (Tangshan) Pharmaceuticals, the Chinese subsidiary of US
speciality pharma concern BMP Sunstone, is acquiring a 75% holding in
Zhangjiakou Shengda Pharmaceutical, a Chinese manufacturer of paediatric
pharmaceuticals and specialising in antibiotic R&D, for around
$4.4m. The terms of the deal, which is expected to be closed during Q4
2008, have yet to be finalised. Sunstone recently acquired a 63.3%
holding in Shanghai Rongheng Pharmaceutical.
COPYRIGHT 2008 Society of Chemical
Industry Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.